

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 213 296 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(43) Date of publication:
12.06.2002 Bulletin 2002/24

(51) Int Cl.7: C07H 17/02, C07D 231/20,
A61K 31/7056, A61P 3/04,
A61P 3/10

(21) Application number: 00954963.5

(86) International application number:
PCT/JP00/05678

(22) Date of filing: 24.08.2000

(87) International publication number:
WO 01/16147 (08.03.2001 Gazette 2001/10)

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

- KATSUNO, Kenji
Kamiina-gun Nagano 399-0601 (JP)
- HIRATOCHI, Masahiro
Kiso-gun, Nagano 399-6101 (JP)
- IYobe, Akira
Minamiazumi-gun Nagano 399-8302 (JP)
- FUJIOKA, Minoru
Okaya-shi Nagano 394-0044 (JP)
- ISAJI, Masayuki
Shiojiri-shi Nagano 399-0704 (JP)

Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 31.08.1999 JP 24680099

(74) Representative:
Baverstock, Michael George Douglas et al
BOULT WADE TENNANT,
Verulam Gardens
70 Gray's Inn Road
London WC1X 8BT (GB)


(71) Applicant: Kissei Pharmaceutical Co., Ltd.
Matsumoto-shi Nagano 399-8710 (JP)

(72) Inventors:

- FUJIKURA, Hideki
Matsumoto-shi Nagano 390-0851 (JP)
- NISHIMURA, Toshihiro
Minamiazumi-gun Nagano 399-8304 (JP)


(54) **GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL COMPOSITIONS
CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF**

(57) The present invention relates to glucopyranosyloxyxypyrazole derivatives represented by the general formula:



while the other represents a lower alkyl group or a halo (lower alkyl) group; and R² represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity on human SGLT2 and are useful as agents for the prevention or treatment of diabetes, diabetic complications or obesity, and to pharmaceutical compositions comprising the same and intermediates thereof.

wherein R¹ represents a hydrogen atom or a lower alkyl group; one of Q¹ and T¹ represents a group represented by the general formula:



EP 1 213 296 A1

Description**Technical Field**

5 [0001] The present invention relates to glucopyranosyloxyypyrazole derivatives or pharmaceutically acceptable salts thereof, which are useful as medicaments, pharmaceutical compositions comprising the same and intermediates thereof.

Background Art


10 [0002] Diabetes is a lifestyle-related disease with the background of change of eating habit and lack of exercise. Hence, diet and exercise therapies are performed on patients with diabetes. Furthermore, when sufficient control and continuous performance are difficult, drug treatment is simultaneously performed. Biguanides, sulfonylureas and insulin 15 sensitivity enhancers have been employed as antidiabetic agents. However, biguanides and sulfonylureas show occasionally adverse effects such as lactic acidosis and hypoglycemia, respectively. When using insulin sensitivity enhancers, adverse effects such as edema occasionally are observed, and it is also concerned in advancing obesity. Therefore, in order to solve these problems, it has been desired to develop antidiabetic agents having a new mechanism.

20 [0003] In recent years, development of new type antidiabetic agents has been progressing, which promote urinary glucose excretion and lower blood glucose level by preventing excess glucose reabsorption at the kidney (J. Clin. Invest., Vol.79, pp.1510-1515 (1987)). In addition, it is reported that SGLT2 (Na⁺/glucose cotransporter 2) is present in the S1 segment of the kidney's proximal tubule and participates mainly in reabsorption of glucose filtrated through glomerular (J. Clin. Invest., Vol.93, pp.397-404 (1994)). Accordingly, inhibiting a human SGLT2 activity prevents reabsorption of excess glucose at the kidney, subsequently promotes excreting excess glucose through the urine, and 25 normalizes blood glucose level. Therefore, fast development of antidiabetic agents, which have a potent inhibitory activity in human SGLT2 and have a new mechanism, has been desired. Also, since such agents promote the excretion of excess glucose through the urine and consequently the glucose accumulation in the body is decreased, they are also expected to have a preventing or alleviating effect on obesity.


30 [0004] As compounds having pyrazole moiety, it is described that WAY-123783 increased the amount of excreted glucose in normal mice. However, its effects in humans are not described at all (J. Med. Chem., Vol. 39, pp. 3920-3928 (1996)).

Disclosure of the Invention

35 [0005] The present invention relates to a glucopyranosyloxyypyrazole derivative represented by the general formula:




45 wherein R¹ represents a hydrogen atom or a lower alkyl group; one of Q¹ and T¹ represents a group represented by the formula:



55 while the other represents a lower alkyl group or a halo(lower alkyl) group; and R² represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or a pharmaceutically acceptable salt thereof.

[0006] Also, the present invention relates to a pharmaceutical composition which comprise as an active ingredient

5 a glucopyranosyloxyprazole derivative represented by the general formula:




10 wherein R¹ represents a hydrogen atom or a lower alkyl group; one of Q¹ and T¹ represents a group represented by the formula:




20 while the other represents a lower alkyl group or a halo(lower alkyl) group; and R² represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or a pharmaceutically acceptable salt thereof.

25 [0007] Furthermore, The present invention relates to a glucopyranosyloxyprazole derivative represented by the general formula:



35 wherein R¹ represents a hydrogen atom or a lower alkyl group; one of Q² and T² represents a 2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy group, while the other represents a lower alkyl group or a halo(lower alkyl) group; and R² represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or a salt thereof, and to a benzylprazole derivative represented by the general formula:




45 wherein R^{2'} represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and R^{3'} represents a lower alkyl group, or a salt thereof.


50 **Best Mode for Carrying Out the Invention**

55 [0008] The present inventors have studied earnestly to find compounds having inhibitory activity in human SGLT2. As a result, it was found that glucopyranosyloxyprazole derivatives represented by the above general formula (I) exhibit excellent inhibitory activity in human SGLT2 as mentioned below, thereby forming the basis of the present invention.

[0009] This is, the present invention relates to a glucopyranosyloxyprazole derivative represented by the general formula:



10 wherein R¹ represents a hydrogen atom or a lower alkyl group; one of Q¹ and T¹ represents a group represented by the formula:



20 while the other represents a lower alkyl group or a halo(lower alkyl) group; and R² represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and an intermediate thereof.

[0010] In the compounds represented by the above general formula (I), the term "lower alkyl group" means a straight-chained or branched alkyl group having 1 to 6 carbon atoms such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a *sec*-butyl group, a *tert*-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a *tert*-pentyl group, a hexyl group or the like; the term "lower alkoxy group" means a straight-chained or branched alkoxy group having 1 to 6 carbon atoms such as a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, a *sec*-butoxy group, a *tert*-butoxy group, a pentyloxy group, an isopentyloxy group, a neopentyloxy group, a *tert*-pentyloxy group, a hexyloxy group or the like; and the term "lower alkylthio group" means a straight-chained or branched alkylthio group having 1 to 6 carbon atoms such as a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, a butylthio group, an isobutylthio group, a *sec*-butylthio group, a *tert*-butylthio group, a pentylthio group, an isopentylthio group, a neopentylthio group, a *tert*-pentylthio group, a hexylthio group or the like. The term "halogen atom" means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom; and the term "halo(lower alkyl) group" means the above lower alkyl group substituted by different or same 1 to 3 halogen atoms as defined above.


[0011] In the substituent R¹, a hydrogen atom or a straight-chained or branched alkyl group having 1 to 3 carbon atoms are preferable; and a hydrogen atom, an ethyl group, a propyl group or an isopropyl group are more preferable. In the substituent R², a straight-chained or branched alkyl group having 1 to 4 carbon atoms, a straight-chained or branched alkoxy group having 1 to 3 carbon atoms, or a straight-chained or branched alkylthio group having 1 to 3 carbon atoms are preferable; and an ethyl group, an ethoxy group, an isopropoxy group or a methylthio group are more preferable. In the substituents Q¹ and T¹, it is preferable that either of them is a straight-chained or branched alkyl group having 1 to 3 carbon atoms, and it is more preferable that either of them is a methyl group.

[0012] For example, the compounds represented by the above general formula (I) of the present invention can be prepared according to the following procedure:

45

50

55



wherein X and Y represent a leaving group such as a halogen atom, a mesyloxy group or a tosyloxy group; R^3 represents a lower alkyl group or a halo(lower alkyl) group; R^4 represents a methyl group or an ethyl group; R^5 represents a lower alkyl group; one of Q^2 and T^2 represents a 2,3,4,6-tetra-O-acetyl- β -D-gluco-pyranosyloxy group, while the other represents a lower alkyl group or a halo(lower alkyl) group; and R^1 , R^2 , Q^1 and T^1 have the same meanings as defined above.

Process 1

[0013] A compound represented by the above general formula (IV) can be prepared by condensing a benzyl derivative represented by the above general formula (II) with a ketoacetate represented by the above general formula (III) in the presence of a base such as sodium hydride or potassium *tert*-butoxide in an inert solvent. As the inert solvent used in the reaction, 1,2-dimethoxyethane, tetrahydrofuran, *N,N*-dimethylformamide, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 1 day, varying based on a used starting material, solvent and reaction temperature.

Process 2

[0014] A pyrazolone derivative represented by the above general formula (V) can be prepared by condensing a compound represented by the above general formula (IV) with hydrazine or hydrazine monohydrate in an inert solvent. As the inert solvent used in the reaction, toluene, tetrahydrofuran, chloroform, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 1 day, varying based on a used starting material, solvent and reaction temperature. The obtained pyrazolone derivative represented by the above general formula (V) can be also used in process 3 after converting into a salt thereof in usual way.

Process 3

[0015]

(1) In case of pyrazolone derivatives represented by the above general formula (V) wherein R^3 is a lower alkyl group, a corresponding compound represented by the above general formula (VII) can be prepared by subjecting a corresponding pyrazolone derivative represented by the above general formula (V) to glycosidation using acetobromo- α -D-glucose in the presence of a base such as silver carbonate in an inert solvent, and subjecting the resulting compound to *N*-alkylation using an alkylating agent represented by the above general formula (VI) in the presence of a base such as potassium carbonate in an inert solvent as occasion demands. As the solvent used in the glycosidation reaction, tetrahydrofuran and the like can be illustrated. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 1 day, depending on the starting material, solvent and reaction temperature used. As the solvent used in the *N*-alkylation reaction, acetonitrile, *N,N*-dimethylformamide, tetrahydrofuran, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 1 day, depending on the starting material, solvent and reaction temperature used.

(2) In the case of pyrazolone derivatives represented by the above general formula (V) wherein R^3 is a halo(lower

alkyl) group, a corresponding compound represented by the above general formula (VII) can be prepared by subjecting a corresponding pyrazolone derivative represented by the above general formula (V) to glycosidation using acetobromo- α -D-glucose in the presence of a base such as potassium carbonate in an inert solvent, and subjecting the resulting compound to *N*-alkylation using an alkylating agent represented by the above general formula (VI) in the presence of a base such as potassium carbonate in an inert solvent as occasion demands. As the solvent used in the glycosidation reaction, acetonitrile, tetrahydrofuran and the like can be illustrated. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 1 day, depending on the starting material, solvent and reaction temperature used. As the solvent used in the *N*-alkylation reaction, acetonitrile, *N,N*-dimethylformamide, tetrahydrofuran, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 1 hour to 1 day, depending on the starting material, solvent and reaction temperature used.


[0016] The obtained compounds represented by the above general formula (VII) can be also used in process 4 after converting into a salt thereof in a usual way.

15 Process 4

[0017] A compound (I) of the present invention can be prepared by subjecting a compound represented by the above general formula (VII) to alkaline hydrolysis. As the solvent used in the reaction, methanol, ethanol, tetrahydrofuran, water, a mixed solvent thereof and the like can be illustrated, and as the base used, sodium hydroxide, sodium ethoxide and the like can be illustrated. The reaction temperature is usually from 0°C to room temperature, and the reaction time is usually from 30 minutes to 6 hours, depending on the starting material, solvent and reaction temperature used.

[0018] Of the compounds represented by the above general formula (I), compounds wherein the substituent R¹ is a lower alkyl group can be prepared according to the following procedure:

25



wherein Q¹, R², R⁵, T¹ and X have the same meanings as defined above.

35

Process 5

[0019] A compound represented by the above general formula (Ib) of the present invention can be prepared by subjecting a compound represented by the above general formula (Ia) of the present invention to *N*-alkylation using an *N*-alkylating agent represented by the above general formula (VI) in the presence of a base such as potassium carbonate or cesium carbonate, and occasionally a catalytic amount of sodium iodide in an inert solvent. As the inert solvent used in the reaction, *N,N*-dimethylformamide, dimethoxyethane, dimethyl sulfoxide, tetrahydrofuran, ethanol, a mixed solvent thereof and the like can be illustrated. The reaction temperature is usually from room temperature to reflux temperature, and the reaction time is usually from 10 minutes to 1 day, depending on the starting material, solvent and reaction temperature used.

[0020] The compounds represented by the above general formula (VII) and salts thereof which are used in the aforementioned production process are compounds useful as intermediates of compounds represented by the above general formula (I) of the present invention. In the compounds represented by the above general formula (VII) as well as the compounds represented by the above general formula (I) of the present invention, it is preferable that either of the substituents Q² and T² is a straight-chained or branched alkyl group having 1 to 3 carbon atoms, and it is more preferable that either of them is a methyl group.

[0021] In the compound represented by the above general formula (V) as starting materials, there are the following three tautomers, depending on the change of reaction conditions:

55

5

10

15

20

wherein R² and R³ have the same meanings as defined above. The compounds represented by the above general formula (V) and salts thereof which are used in the aforementioned production process are compounds useful as intermediates of compounds represented by the above general formula (I) of the present invention. In the compounds represented by the above general formula (V) as well as the compounds represented by the above general formula (I) of the present invention, it is preferable that the substituent R³ is a straight-chained or branched alkyl group having 1 to 3 carbon atoms, and it is more preferable that the substituent R³ is a methyl group.

[0022] The compounds represented by the above general formula (I) of the present invention obtained by the above production processes can be isolated and purified by conventional separation means such as fractional recrystallization, purification using chromatography and solvent extraction.

[0023] The glucopyranosyloxyprazole derivatives represented by the above general formula (I) of the present invention can be converted into their pharmaceutically acceptable salts in the usual way. Examples of such salts include acid addition salts with mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid and the like, acid addition salts with organic acids such as formic acid, acetic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, propionic acid, citric acid, succinic acid, tartaric acid, fumaric acid, butyric acid, oxalic acid, malonic acid, maleic acid, lactic acid, malic acid, carbonic acid, glutamic acid, aspartic acid and the like, and salts with inorganic bases such as a sodium salt, a potassium salt and the like.


[0024] The compounds represented by the above general formula (I) of the present invention include their solvates with pharmaceutically acceptable solvents such as ethanol and water.

[0025] The compounds represented by the above general formula (I) of the present invention have excellent inhibitory activity on human SGLT2 and are extremely useful as agents for the prevention or treatment of diabetes, diabetic complications, obesity and the like. For example, in the following assay for inhibitory effect on human SGLT2 activity, the compounds of the present invention exerted a potent inhibitory activity on human SGLT2. On the other hand, since WAY-123783 has an extremely weak inhibitory activity on human SGLT2, it cannot be expected to exert a sufficient effect as a human SGLT2 inhibitor.

[0026] When the pharmaceutical compositions of the present invention are employed in practical treatment, various dosage forms are used depending on their uses. As examples of the dosage forms, powders, granules, fine granules, dry syrups, tablets, capsules, injections, solutions, ointments, suppositories, poultices and the like are illustrated, which are orally or parenterally administered.

[0027] These pharmaceutical compositions can be prepared by admixing with or by diluting and dissolving an appropriate pharmaceutical additive such as excipients, disintegrators, binders, lubricants, diluents, buffers, isotonicities, antiseptics, moistening agents, emulsifiers, dispersing agents, stabilizing agents, dissolving aids and the like, and formulating the mixture in the conventional manner.

[0028] When the pharmaceutical compositions of the present invention are employed in practical treatment, the dosage of a compound represented by the above general formula (I) or a pharmaceutically acceptable salt thereof as the active ingredient is appropriately decided depending on the age, sex, body weight and degree of symptoms and treatment of each patient, which is approximately within the range of from 0.1 to 1,000mg per day per adult human in the case of oral administration and approximately within the range of from 0.01 to 300mg per day per adult human in the case of parenteral administration, and the daily dose can be divided into several doses per day and administered suitably.



Examples

[0029] The present invention is further illustrated in more detail by way of the following Reference Examples, Examples and Test Examples. However, the present invention is not limited thereto.

5

Example 11,2-Dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3H-pyrazol-3-one

[0030] To a solution of 4-isopropoxybenzylalcohol (0.34g) in tetrahydrofuran (6mL) were added triethylamine (0.28mL) and methanesulfonyl chloride (0.16mL), and the mixture was stirred at room temperature for 30 minutes. The resulting insoluble material was removed by filtration. The obtained solution of 4-isopropoxybenzyl methanesulfonate in tetrahydrofuran was added to a suspension of sodium hydride (60%, 81mg) and methyl acetoacetate (0.20mL) in 1,2-dimethoxyethane (10mL), and the mixture was stirred at 80°C overnight. The reaction mixture was poured into a saturated aqueous sodium hydrogen carbonate solution, and the resulting mixture was extracted with diethyl ether. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was dissolved in toluene (5mL). Anhydrous hydrazine (0.19mL) was added to the solution, and the mixture was stirred at 80°C overnight. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: dichloromethane/methanol = 10/1) to give 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3H-pyrazol-3-one (95mg).

¹H-NMR (500MHz, DMSO-d₆) δ ppm:

1.22 (6H, d, J=6.0Hz), 1.99 (3H, s), 3.45 (2H, s), 4.40-4.60 (1H, m), 6.65-6.80 (2H, m), 6.95-7.10 (2H, m)

Example 2

25

1,2-Dihydro-5-methyl-4-[(4-propylphenyl)methyl]-3H-pyrazol-3-one

[0031] The title compound was prepared in a similar manner to that described in Example 1 using 4-propylbenzyl alcohol instead of 4-isopropoxybenzyl alcohol.

¹H-NMR (500MHz, DMSO-d₆) δ ppm:

0.75-0.95 (3H, m), 1.45-1.65 (2H, m), 1.99 (3H, s), 2.40-2.55 (2H, m), 3.32 (2H, s), 6.95-7.10 (4H, m)

Example 31,2-Dihydro-4-[(4-isobutylphenyl)methyl]-5-methyl-3H-pyrazol-3-one

[0032] The title compound was prepared in a similar manner to that described in Example 1 using 4-isobutylbenzyl alcohol instead of 4-isopropoxybenzyl alcohol.

¹H-NMR (500MHz, DMSO-d₆) δ ppm:

0.83 (6H, d, J=6.6Hz), 1.70-1.85 (1H, m), 1.99 (3H, s), 2.30-2.45 (2H, m), 3.50 (2H, s), 6.90-7.10 (4H, m)

Example 41,2-Dihydro-5-methyl-4-[(4-propoxyphenyl)methyl]-3H-pyrazol-3-one

45

[0033] The title compound was prepared in a similar manner to that described in Example 1 using 4-propoxybenzyl alcohol instead of 4-isopropoxybenzyl alcohol.

¹H-NMR (500MHz, DMSO-d₆) δ ppm:

0.95 (3H, t, J=7.4Hz), 1.60-1.75 (2H, m), 1.98 (3H, s), 3.46 (2H, s), 3.75-3.90 (2H, m), 6.70-6.85 (2H, m), 6.95-7.10 (2H, m)

Example 54-[(4-Ethoxyphenyl)methyl]-1,2-dihydro-5-methyl-3H-pyrazol-3-one

55

[0034] The title compound was prepared in a similar manner to that described in Example 1 using 4-ethoxybenzyl alcohol instead of 4-isopropoxybenzyl alcohol.

¹H-NMR (500MHz, DMSO-d₆) δ ppm:

1.20-1.35 (3H, m), 1.98 (3H, s), 3.46 (2H, s), 3.85-4.05 (2H, m), 6.70-6.85 (2H, m), 6.95-7.10 (2H, m)

Example 6

5 1,2-Dihydro-5-methyl-4-[(4-trifluoromethylphenyl)methyl]-3H-pyrazol-3-one

[0035] The title compound was prepared in a similar manner to that described in Example 1 using 4-trifluoromethylbenzyl alcohol instead of 4-isopropoxybenzyl alcohol.

1H-NMR (500MHz, DMSO-d₆) δ ppm:

10 2.02 (3H, s), 3.64 (2H, s), 7.30-7.45 (2H, m), 7.55-7.70 (2H, m)

Example 7

4-[(4-tert-Butylphenyl)methyl]-1,2-dihydro-5-methyl-3H-pyrazol-3-one

15 [0036] The title compound was prepared in a similar manner to that described in Example 1 using 4-tert-butylbenzyl alcohol instead of 4-isopropoxybenzyl alcohol.

1H-NMR (500MHz, DMSO-d₆) δ ppm:

1.24 (9H, s), 2.01 (3H, s), 3.49 (2H, s), 7.00-7.15 (2H, m), 7.15-7.30 (2H, m)

20 Example 8

4-[(4-Butoxyphenyl)methyl]-1,2-dihydro-5-methyl-3H-pyrazol-3-one

25 [0037] The title compound was prepared in a similar manner to that described in Example 1 using 4-butoxybenzyl alcohol instead of 4-isopropoxybenzyl alcohol.

1H-NMR (500MHz, DMSO-d₆) δ ppm:

0.91 (3H, t, J=7.4Hz), 1.30-1.50 (2H, m), 1.55-1.75 (2H, m), 1.98 (3H, s), 3.46 (2H, s), 3.80-3.95 (2H, m), 6.70-6.85 (2H, m), 6.95-7.10 (2H, m)

30 Example 9

1,2-Dihydro-5-methyl-4-[(4-methylthiophenyl)methyl]-3H-pyrazol-3-one

35 [0038] The title compound was prepared in a similar manner to that described in Example 1 using 4-(methylthio)benzyl alcohol instead of 4-isopropoxybenzyl alcohol.

1H-NMR (500MHz, DMSO-d₆) δ ppm:

1.99 (3H, s), 2.42 (3H, s), 3.50 (2H, s), 7.05-7.20 (4H, m)

40 Example 10

5-Ethyl-1,2-dihydro-4-[(4-methylthiophenyl)methyl]-3H-pyrazol-3-one

45 [0039] The title compound was prepared in a similar manner to that described in Example 1 using 4-(methylthio)benzyl alcohol instead of 4-isopropoxybenzyl alcohol and using methyl 3-oxopentanoate instead of methyl acetoacetate.

1H-NMR (500MHz, DMSO-d₆) δ ppm:

1.02 (3H, t, J=7.6Hz), 2.39 (2H, q, J=7.6Hz), 2.42 (3H, s), 3.51 (2H, s), 7.05-7.20 (4H, m)

50 Example 11

1,2-Dihydro-4-[(4-isopropylphenyl)methyl]-5-methyl-3H-pyrazol-3-one

55 [0040] To a suspension of sodium hydride (60%, 40mg) in 1,2-dimethoxyethane (1mL) were added methyl acetoacetate (0.11mL), 4-isopropylbenzyl chloride (0.17g) and a catalytic amount of sodium iodide, and the mixture was stirred at 80°C overnight. The reaction mixture was poured into a saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with diethyl ether. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was dissolved in toluene (1mL).

Anhydrous hydrazine (0.094mL) was added to the solution, and the mixture was stirred at 80°C overnight. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: dichloromethane/methanol = 10/1) to give 1,2-dihydro-4-[(4-isopropylphenyl)methyl]-5-methyl-3*H*-pyrazol-3-one (0.12g).

5 $^1\text{H-NMR}$ (500MHz, DMSO- d_6) δ ppm:
 1.16 (6H, d, $J=6.9\text{Hz}$), 2.01 (3H, s), 2.70-2.90 (1H, m), 3.49 (2H, s), 6.95-7.20 (4H, m)

Example 12

10 4-[(4-Ethylphenyl)methyl]-1,2-dihydro-5-methyl-3*H*-pyrazol-3-one

[0041] The title compound was prepared in a similar manner to that described in Example 11 using 4-ethylbenzyl chloride instead of 4-isopropylbenzyl chloride.

15 $^1\text{H-NMR}$ (500MHz, DMSO- d_6) δ ppm:
 1.13 (3H, t, $J=7.6\text{Hz}$), 2.00 (3H, s), 2.45-2.60 (2H, m), 3.49 (2H, s), 7.00-7.15 (4H, m)

Example 13

20 1,2-Dihydro-5-methyl-4-[(4-methylphenyl)methyl]-3*H*-pyrazol-3-one

[0042] The title compound was prepared in a similar manner to that described in Example 11 using 4-methylbenzyl bromide instead of 4-isopropylbenzyl chloride.

25 $^1\text{H-NMR}$ (500MHz, DMSO- d_6) δ ppm:
 1.98 (3H, s), 2.23 (3H, s), 3.48 (2H, s), 6.95-7.10 (4H, m)

Reference Example 1

4-Benzyl-1,2-dihydro-5-trifluoromethyl-3*H*-pyrazol-3-one

30 [0043] The title compound was prepared in a similar manner to that described in Example 11 using ethyl trifluoroacetatoacetate instead of methyl acetoacetate and using benzyl bromide instead of 4-isopropylbenzyl chloride.

$^1\text{H-NMR}$ (500MHz, DMSO- d_6) δ ppm:
 3.73 (2H, s), 7.05-7.35 (5H, m), 12.50-13.10 (1H, brs)

35 Example 14

1,2-Dihydro-4-[(4-methoxyphenyl)methyl]-5-methyl-3*H*-pyrazol-3-one

40 [0044] The title compound was prepared in a similar manner to that described in Example 11 using 4-methoxybenzyl bromide instead of 4-isopropylbenzyl chloride.

$^1\text{H-NMR}$ (500MHz, DMSO- d_6) δ ppm:
 1.99 (3H, s), 3.47 (2H, s), 3.69 (3H, s), 6.75-6.85 (2H, m), 7.00-7.10 (2H, m), 8.70-11.70 (2H, br)

45 Reference Example 2

4-Benzyl-1,2-dihydro-5-methyl-3*H*-pyrazol-3-one

50 [0045] The title compound was prepared in a similar manner to that described in Example 11 using benzyl bromide instead of 4-isopropylbenzyl chloride.

$^1\text{H-NMR}$ (500MHz, DMSO- d_6) δ ppm:
 2.00 (3H, s), 3.54 (2H, s), 7.05-7.30 (5H, s)

Example 15

55 4-[(4-Isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole

[0046] To a suspension of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3*H*-pyrazol-3-one (46mg), aceto-bromo- α -D-glucose (99mg) and 4A molecular sieves in tetrahydrofuran (3mL) was added silver carbonate (66mg), and

the mixture was stirred under shading the light at 65°C overnight. The reaction mixture was purified by column chromatography on aminopropyl silica gel (eluent: tetrahydrofuran). Further purification by preparative thin layer chromatography on silica gel (developing solvent: ethyl acetate/hexane = 2/1) afforded 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole (42mg).

5 1 H-NMR (500MHz, CDCl₃) δ ppm: 1.25-1.35 (6H, m), 1.88 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.05 (3H, s), 2.10 (3H, s), 3.45-3.65 (2H, m), 3.80-3.90 (1H, m), 4.13 (1H, dd, J=2.3, 12.4Hz), 4.31 (1H, dd, J=4.0, 12.4Hz), 4.40-4.55 (1H, m), 5.15-5.35 (3H, m), 5.50-5.60 (1H, m), 6.70-6.80 (2H, m), 6.95-7.05 (2H, m)

10 Example 16

5-Methyl-4-[(4-propylphenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole

[0047] The title compound was prepared in a similar manner to that described in Example 15 using 1,2-dihydro-5-methyl-4-[(4-propylphenyl)methyl]-3*H*-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3*H*-pyrazol-3-one.

15 1 H-NMR (500MHz, CDCl₃) δ ppm: 0.91 (3H, t, J=7.3Hz), 1.50-1.65 (2H, m), 1.86 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.05 (3H, s), 2.10 (3H, s), 2.45-2.55 (2H, m), 3.55 (1H, d, J=15.8Hz), 3.63 (1H, d, J=15.8Hz), 3.80-3.90 (1H, m), 4.13 (1H, dd, J=2.3, 12.4Hz), 4.30 (1H, dd, J=3.9, 12.4Hz), 5.15-5.35 (3H, m), 5.50-5.60 (1H, m), 7.00-7.20 (4H, m)

20 Example 17

4-[(4-Isobutylphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole

[0048] The title compound was prepared in a similar manner to that described in Example 15 using 1,2-dihydro-4-[(4-isobutylphenyl)methyl]-5-methyl-3*H*-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3*H*-pyrazol-3-one.

25 1 H-NMR (500MHz, CDCl₃) δ ppm: 0.87 (6H, d, J=6.6Hz), 1.70-1.85 (1H, m), 1.87 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06 (3H, s), 2.10 (3H, s), 2.40 (2H, d, J=7.2Hz), 3.56 (1H, d, J=15.8Hz), 3.63 (1H, d, J=15.8Hz), 3.80-3.90 (1H, m), 4.14 (1H, dd, J=2.3, 12.4Hz), 4.31 (1H, dd, J=4.0, 12.4Hz), 5.15-5.35 (3H, m), 5.50-5.60 (1H, m), 6.95-7.10 (4H, m)

30 Example 18

5-Methyl-4-[(4-propoxyphenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole

[0049] The title compound was prepared in a similar manner to that described in Example 15 using 1,2-dihydro-5-methyl-4-[(4-propoxyphenyl)methyl]-3*H*-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3*H*-pyrazol-3-one.

35 1 H-NMR (500MHz, CDCl₃) δ ppm: 1.01 (3H, t, J=7.4Hz), 1.70-1.85 (2H, m), 1.89 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06 (3H, s), 2.10 (3H, s), 3.53 (1H, d, J=15.7Hz), 3.59 (1H, d, J=15.7Hz), 3.80-3.95 (3H, m), 4.14 (1H, dd, J=2.3, 12.4Hz), 4.31 (1H, dd, J=4.0, 12.4Hz), 5.15-5.35 (3H, m), 5.50-5.60 (1H, m), 6.70-6.80 (2H, m), 6.95-7.10 (2H, m)

40 Example 19

4-[(4-Ethoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole

[0050] The title compound was prepared in a similar manner to that described in Example 15 using 4-[(4-ethoxyphenyl)-methyl]-1,2-dihydro-5-methyl-3*H*-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3*H*-pyrazol-3-one.

45 1 H-NMR (500MHz, CDCl₃) δ ppm: 1.38 (3H, t, J=7.0Hz), 1.89 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06 (3H, s), 2.10 (3H, s), 3.53 (1H, d, J=15.8Hz), 3.59 (1H, d, J=15.8Hz), 3.80-3.90 (1H, m), 3.98 (2H, q, J=7.0Hz), 4.13 (1H, dd, J=2.3, 12.4Hz), 4.31 (1H, dd, J=4.0, 12.4), 5.15-5.30 (3H, m), 5.50-5.60 (1H, m), 6.70-6.80 (2H, m), 6.95-7.10 (2H, m)

Example 205-Methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-trifluoromethylphenyl)methyl]-1H-pyrazole

5 [0051] The title compound was prepared in a similar manner to that described in Example 15 using 1,2-dihydro-5-methyl-4-[(4-trifluoromethylphenyl)methyl]-3H-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3H-pyrazol-3-one.
¹H-NMR (500MHz, CDCl₃) δ ppm: 1.85 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06 (3H, s), 2.14 (3H, s), 3.65 (1H, d, J=15.9Hz), 3.71 (1H, d, J=15.9Hz), 3.80-3.90 (1H, m), 4.14 (1H, dd, J=2.4, 12.4Hz), 4.31 (1H, dd, J=4.0, 12.4Hz), 5.15-5.40 (3H, m), 5.55-5.65 (1H, m), 7.20-7.30 (2H, m), 7.45-7.55 (2H, m)

Example 214-[(4-tert-Butylphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1H-pyrazole

15 [0052] The title compound was prepared in a similar manner to that described in Example 15 using 4-[(4-tert-butylphenyl)methyl]-1,2-dihydro-5-methyl-3H-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3H-pyrazol-3-one.
20 ¹H-NMR (500MHz, CDCl₃) δ ppm: 1.27 (9H, s), 1.84 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06 (3H, s), 2.14 (3H, s), 3.56 (1H, d, J=15.8Hz), 3.64 (1H, d, J=15.8Hz), 3.80-3.90 (1H, m), 4.13 (1H, dd, J=2.3, 12.4Hz), 4.31 (1H, dd, J=4.0, 12.4Hz), 5.15-5.30 (3H, m), 5.50-5.60 (1H, m), 7.00-7.10 (2H, m), 7.20-7.30 (2H, m)

Example 224-[(4-Butoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1H-pyrazole

25 [0053] The title compound was prepared in a similar manner to that described in Example 15 using 4-[(4-butoxyphenyl)methyl]-1,2-dihydro-5-methyl-3H-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3H-pyrazol-3-one.
30 ¹H-NMR (500MHz, CDCl₃) δ ppm: 0.96 (3H, t, J=7.4Hz), 1.40-1.55 (2H, m), 1.65-1.80 (2H, m), 1.88 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06 (3H, s), 2.10 (3H, s), 3.52 (1H, d, J=15.8Hz), 3.59 (1H, d, J=15.8Hz), 3.80-3.90 (1H, m), 3.91 (2H, t, J=6.5Hz), 4.13 (1H, dd, J=2.3, 12.4Hz), 4.31 (1H, dd, J=4.0, 12.4Hz), 5.15-5.30 (3H, m), 5.50-5.60 (1H, m), 6.70-6.80 (2H, m), 6.95-7.10 (2H, m)

Example 235-Methyl-4-[(4-methylthiophenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1H-pyrazole

40 [0054] The title compound was prepared in a similar manner to that described in Example 15 using 1,2-dihydro-5-methyl-4-[(4-methylthiophenyl)methyl]-3H-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3H-pyrazol-3-one.
45 ¹H-NMR (500MHz, CDCl₃) δ ppm: 1.88 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.07 (3H, s), 2.12 (3H, s), 2.44 (3H, s), 3.50-3.65 (2H, m), 3.80-3.90 (1H, m), 4.13 (1H, dd, J=2.4, 12.4Hz), 4.31 (1H, dd, J=4.1, 12.4Hz), 5.15-5.30 (3H, m), 5.55-5.65 (1H, m), 7.00-7.10 (2H, m), 7.10-7.20 (2H, m), 8.65-8.85 (1H, brs)

Example 245-Ethyl-4-[(4-methylthiophenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1H-pyrazole

50 [0055] The title compound was prepared in a similar manner to that described in Example 15 using 5-ethyl-1,2-dihydro-4-[(4-methylthiophenyl)methyl]-3H-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3H-pyrazol-3-one.
55 ¹H-NMR (500MHz, CDCl₃) δ ppm: 1.13 (3H, t, J=7.6Hz), 1.88 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06 (3H, s), 2.44 (3H, s), 2.45-2.55 (2H, m), 3.50-3.70 (2H, m), 3.80-3.90 (1H, m), 4.05-4.20 (1H, m), 4.31 (1H, dd, J=4.0, 12.4Hz), 5.15-5.35 (3H, m), 5.55-5.65 (1H, m),

7.00-7.10 (2H, m), 7.10-7.20 (2H, m), 8.80-9.20 (1H, brs)

Example 25

4-[(4-Isopropylphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1H-pyrazole

[0056] The title compound was prepared in a similar manner to that described in Example 15 using 1,2-dihydro-4-[(4-isopropylphenyl)methyl]-5-methyl-3H-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3H-pyrazol-3-one.

1H-NMR (500MHz, CDCl₃) δ ppm: 1.20 (6H, d, J=6.9Hz), 1.85 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06 (3H, s), 2.13 (3H, s), 2.75-2.90 (1H, m), 3.56 (1H, d, J=15.8Hz), 3.63 (1H, d, J=15.8Hz), 3.80-3.90 (1H, m), 4.05-4.20 (1H, m), 4.31 (1H, dd, J=4.0, 12.4Hz), 5.15-5.35 (3H, m), 5.50-5.60 (1H, m), 7.00-7.15 (4H, m), 8.70-9.30 (1H, brs)

Example 26

4-[(4-Methylthiophenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethyl-1H-pyrazole

[0057] To a solution of 1,2-dihydro-4-[(4-methylthiophenyl)-methyl]-5-trifluoromethyl-3H-pyrazol-3-one (2.0g) in acetonitrile (100mL) were added acetobromo- α -D-glucose (3.1g) and potassium carbonate (1.1g), and the mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium hydrogen carbonate solution and brine, and dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: hexane/ethyl acetate = 1/1) to give 4-[(4-methylthiophenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethyl-1H-pyrazole (2.0g).

1H-NMR (500MHz, CDCl₃) δ ppm: 1.91 (3H, s), 2.03 (3H, s), 2.04 (3H, s), 2.09 (3H, s), 2.45 (3H, s), 3.73 (2H, s), 3.75-3.90 (1H, m), 4.15-4.35 (2H, m), 5.15-5.65 (4H, m), 7.00-7.20 (4H, m)

Example 27

4-Benzyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethyl-1H-pyrazole

[0058] The title compound was prepared in a similar manner to that described in Example 26 using 4-benzyl-1,2-dihydro-5-trifluoromethyl-3H-pyrazol-3-one instead of 1,2-dihydro-4-[(4-methylthiophenyl)methyl]-5-trifluoromethyl-3H-pyrazol-3-one.

1H-NMR (500MHz, CDCl₃) δ ppm: 1.89 (3H, s), 2.02 (3H, s), 2.04 (3H, s), 2.08 (3H, s), 3.70-3.90 (3H, m), 4.15-4.30 (2H, m), 5.10-5.50 (4H, m), 7.10-7.30 (5H, m)

Example 28

4-[(4-Methoxyphenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethyl-1H-pyrazole

[0059] The title compound was prepared in a similar manner to that described in Example 26 using 1,2-dihydro-4-[(4-methoxyphenyl)methyl]-5-trifluoromethyl-3H-pyrazol-3-one instead of 1,2-dihydro-4-[(4-methylthiophenyl)methyl]-5-trifluoromethyl-3H-pyrazol-3-one.

1H-NMR (400MHz, CDCl₃) δ ppm: 1.93 (3H, s), 2.03 (3H, s), 2.05 (3H, s), 2.09 (3H, s), 3.65-3.75 (2H, m), 3.77 (3H, s), 3.75-3.90 (1H, m), 4.15-4.35 (2H, m), 5.10-5.45 (4H, m), 6.75-6.85 (2H, m), 7.00-7.15 (2H, m)

Example 29

4-[(4-Methoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1H-pyrazole

[0060] The title compound was prepared in a similar manner to that described in Example 15 using 1,2-dihydro-4-[(4-methoxyphenyl)methyl]-5-methyl-3H-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3H-pyrazol-3-one.

5 ¹H-NMR (400MHz, CDCl₃) δ ppm:

1.89 (3H, s), 2.02 (3H, s), 2.03 (3H, s), 2.05 (3H, s), 2.10 (3H, s), 3.45-3.65 (2H, m), 3.76 (3H, s), 3.80-3.90 (1H, m), 4.11 (1H, dd, J=2.2, 12.4Hz), 4.30 (1H, dd, J=4.0, 12.4Hz), 5.15-5.35 (3H, m), 5.50-5.60 (1H, m), 6.70-6.85 (2H, m), 7.00-7.10 (2H, m)

Example 30

4-Benzyl-5-methyl-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-1*H*-pyrazole

10 [0061] The title compound was prepared in a similar manner to that described in Example 15 using 4-benzyl-1,2-dihydro-5-methyl-3*H*-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxypyhenyl)methyl]-5-methyl-3*H*-pyrazol-3-one. ¹H-NMR (400MHz, CDCl₃) δ ppm:

1.86 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06 (3H, s), 2.11 (3H, s), 3.59 (1H, d, J=15.8Hz), 3.66 (1H, d, J=15.8Hz), 3.80-3.90 (1H, m), 4.11 (1H, dd, J=2.3, 12.4Hz), 4.30 (1H, dd, J=4.0, 12.4Hz), 5.15-5.30 (3H, m), 5.50-5.65 (1H, m), 7.05-7.30 (5H, m), 8.75-9.55 (1H, brs)

Example 31

4-[(4-Methoxyphenyl)methyl]-1,5-dimethyl-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)pyrazole

20 [0062] A suspension of 4-[(4-methoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-1*H*-pyrazole (18mg), potassium carbonate (14mg) and iodomethane (4.7mg) in acetonitrile (2mL) was stirred at 75°C overnight. The reaction mixture was filtered through celite®, and the solvent of the filtrate was removed under reduced pressure. The residue was purified by preparative thin layer chromatography (developing solvent: benzene/acetone = 2/1) to give 4-[(4-methoxyphenyl)methyl]-1,5-dimethyl-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)pyrazole (4mg).

25 ¹H-NMR (500MHz, CDCl₃) δ ppm:

1.90 (3H, s), 2.01 (3H, s), 2.03 (3H, s), 2.06 (3H, s), 2.07 (3H, s), 3.45-3.60 (2H, m), 3.60 (3H, s), 3.76 (3H, s), 3.80-3.90 (1H, m), 4.13 (1H, dd, J=2.4, 12.4Hz), 4.29 (1H, dd, J=4.1, 12.4Hz), 5.15-5.30 (3H, m), 5.50-5.60 (1H, m), 6.70-6.80 (2H, m), 7.00-7.10 (2H, m)

Example 32

1-Methyl-4-[(4-methylthiophenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-5-trifluoromethylpyrazole

35 [0063] A suspension of 4-[(4-methylthiophenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-5-trifluoromethyl-1*H*-pyrazole (30mg), potassium carbonate (8.0mg) and iodomethane (8.2mg) in tetrahydrofuran (1mL) was stirred at 75°C overnight. The reaction mixture was filtered through celite®, and the solvent of the filtrate was removed under reduced pressure. The residue was purified by preparative thin layer chromatography (developing solvent: dichloromethane/ethyl acetate = 5/1) to give 1-methyl-4-[(4-methylthiophenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-5-trifluoromethylpyrazole (13mg).

40 ¹H-NMR (500MHz, CDCl₃) δ ppm:

1.89 (3H, s), 2.02 (3H, s), 2.04 (3H, s), 2.07 (3H, s), 2.44 (3H, s), 3.65-3.95 (6H, m), 4.14 (1H, dd, J=2.3, 12.4Hz), 4.29 (1H, dd, J=4.3, 12.4Hz), 5.15-5.35 (3H, m), 5.50-5.65 (1H, m), 7.00-7.20 (4H, m)

45

Example 33

1-Ethyl-4-[(4-methylthiophenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-5-trifluoromethylpyrazole

50 [0064] The title compound was prepared in a similar manner to that described in Example 32 using iodoethane instead of iodomethane.

¹H-NMR (500MHz, CDCl₃) δ ppm:

1.40 (3H, t, J=7.2Hz), 1.90 (3H, s), 2.02 (3H, s), 2.04 (3H, s), 2.06 (3H, s), 2.44 (3H, s), 3.72 (2H, s), 3.80-3.90 (1H, m), 4.05-4.20 (3H, m), 4.27 (1H, dd, J=4.5, 12.4Hz), 5.10-5.35 (3H, m), 5.55-5.65 (1H, m), 7.00-7.10 (2H, m), 7.10-7.20 (2H, m)

Example 344-[(4-Methylthiophenyl)methyl]-1-propyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethylpyrazole

5 [0065] The title compound was prepared in a similar manner to that described in Example 32 using iodopropane instead of iodomethane.

1H-NMR (500MHz, CDCl₃) δ ppm: 0.92 (3H, t, J=7.4Hz), 1.75-1.90 (2H, m), 1.89 (3H, s), 2.02 (3H, s), 2.04 (3H, s), 2.06 (3H, s), 2.44 (3H, s), 3.72 (2H, s), 3.80-3.90 (1H, m), 3.90-4.05 (2H, m), 4.12 (1H, dd, J=2.3, 12.4Hz), 4.27 (1H, dd, J=4.5, 12.4Hz), 5.10-5.35 (3H, m), 5.55-5.65 (1H, m), 7.00-7.10 (2H, m), 7.10-7.20 (2H, m)

Example 353-(β -D-Glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-5-methyl-1H-pyrazole

15 [0066] To a solution of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1H-pyrazole (61mg) in ethanol (3mL) was added 1N aqueous sodium hydroxide solution (0.53mL), and the mixture was stirred at room temperature for 2 hours. The solvent was removed under reduced pressure, and the residue was purified by solid phase extraction on ODS (washing solvent: distilled water, eluent: methanol) to give 3-(β -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-5-methyl-1H-pyrazole (39mg).

20 1H-NMR (500MHz, CD₃OD) δ ppm: 1.26 (6H, d, J=5.9Hz), 2.05 (3H, s), 3.25-3.45 (4H, m), 3.55-3.75 (3H, m), 3.75-3.90 (1H, m), 4.45-4.60 (1H, m), 5.00-5.10 (1H, m), 6.70-6.80 (2H, m), 7.00-7.15 (2H, m)

Example 363-(β -D-Glucopyranosyloxy)-5-methyl-4-[(4-propylphenyl)-methyl]-1H-pyrazole

25 [0067] The title compound was prepared in a similar manner to that described in Example 35 using 5-methyl-4-[(4-propylphenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1H-pyrazole instead of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1H-pyrazole.

30 1H-NMR (500MHz, CD₃OD) δ ppm: 0.91 (3H, t, J=7.5Hz), 1.50-1.65 (2H, m), 2.05 (3H, s), 2.45-2.60 (2H, m), 3.25-3.45 (4H, m), 3.55-3.75 (3H, m), 3.83 (1H, d, J=11.9Hz), 5.00-5.10 (1H, m), 7.00-7.15 (4H, m)

Example 373-(β -D-Glucopyranosyloxy)-4-[(4-isobutylphenyl)methyl]-5-methyl-1H-pyrazole

35 [0068] The title compound was prepared in a similar manner to that described in Example 35 using 4-[(4-isobutylphenyl)-methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1H-pyrazole instead of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1H-pyrazole.

40 1H-NMR (500MHz, CD₃OD) δ ppm: 0.87 (6H, d, J=6.6Hz), 1.70-1.90 (1H, m), 2.04 (3H, s), 2.41 (2H, d, J=7.1Hz), 3.25-3.45 (4H, m), 3.55-3.90 (4H, m), 5.00-5.10 (1H, m), 6.95-7.15 (4H, m)

Example 383-(β -D-Glucopyranosyloxy)-5-methyl-4-[(4-propoxyphenyl)-methyl]-1H-pyrazole

45 [0069] The title compound was prepared in a similar manner to that described in Example 35 using 5-methyl-4-[(4-propoxyphenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1H-pyrazole instead of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1H-pyrazole.

50 1H-NMR (500MHz, CD₃OD) δ ppm: 1.02 (3H, t, J=7.4Hz), 1.65-1.80 (2H, m), 2.05 (3H, s), 3.25-3.45 (4H, m), 3.60-3.75 (3H, m), 3.80-3.90 (3H, m), 5.00-5.10 (1H, m), 6.70-6.85 (2H, m), 7.05-7.15 (2H, m)

Example 394-[(4-Ethoxyphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-methyl-1*H*-pyrazole

5 [0070] The title compound was prepared in a similar manner to that described in Example 35 using 4-[(4-ethoxyphenyl)-methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole instead of 4-[(4-isopropoxyphe-
nyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.
¹H-NMR (500MHz, CD₃OD) δ ppm:
 1.34 (3H, t, J=7.0Hz), 2.05 (3H, s), 3.25-3.45 (4H, m), 3.60-3.75 (3H, m), 3.80-3.90 (1H, m), 3.97 (2H, q, J=7.0Hz),
 10 5.00-5.10 (1H, m), 6.70-6.85 (2H, m), 7.05-7.15 (2H, m)

Example 403-(β -D-Glucopyranosyloxy)-5-methyl-4-[(4-trifluoromethylphenyl)methyl]-1*H*-pyrazole

15 [0071] The title compound was prepared in a similar manner to that described in Example 35 using 5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-4-[(4-trifluoromethylphenyl)methyl]-1*H*-pyrazole instead of 4-[(4-isopropoxyphe-
nyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.
¹H-NMR (500MHz, CD₃OD) δ ppm:
 20 2.08 (3H, s), 3.20-3.40 (4H, m), 3.67 (1H, dd, J=5.0, 11.9Hz), 3.75-3.90 (3H, m), 5.00-5.10 (1H, m), 7.30-7.45 (2H, m),
 7.45-7.60 (2H, m)

Example 414-[(4-*tert*-Butylphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-methyl-1*H*-pyrazole

25 [0072] The title compound was prepared in a similar manner to that described in Example 35 using 4-[(4-*tert*-butylphenyl)-methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole instead of 4-[(4-isopropoxyphe-
nyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.
¹H-NMR (500MHz, CD₃OD) δ ppm:
 30 1.28 (9H, s), 2.06 (3H, s), 3.25-3.45 (4H, m), 3.60-3.90 (4H, m), 5.00-5.10 (1H, m), 7.05-7.15 (2H, m), 7.20-7.30 (2H, m)

Example 424-[(4-Butoxyphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-methyl-1*H*-pyrazole

35 [0073] The title compound was prepared in a similar manner to that described in Example 35 using 4-[(4-butoxyphenyl)-methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole instead of 4-[(4-isopropoxyphe-
nyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.
¹H-NMR (500MHz, CD₃OD) δ ppm:
 40 0.97 (3H, t, J=7.4Hz), 1.40-1.55 (2H, m), 1.65-1.80 (2H, m), 2.05 (3H, s), 3.30-3.45 (4H, m), 3.60-3.75 (3H, m), 3.83
 (1H, d, J=12.0Hz), 3.91 (2H, t, J=6.4Hz), 5.00-5.10 (1H, m), 6.70-6.85 (2H, m), 7.05-7.15 (2H, m)

Example 433-(β -D-Glucopyranosyloxy)-5-methyl-4-[(4-methylthiophenyl)methyl]-1*H*-pyrazole

45 [0074] The title compound was prepared in a similar manner to that described in Example 35 using 5-methyl-4-[(4-methylthiophenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole instead of 4-[(4-isopropoxyphe-
nyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.
¹H-NMR (500MHz, CD₃OD) δ ppm:
 50 2.06 (3H, s), 2.42 (3H, s), 3.20-3.45 (4H, m), 3.55-3.75 (3H, m), 3.80-3.90 (1H, m), 5.00-5.10 (1H, m), 7.05-7.20 (4H, m)

Example 445-Ethyl-3-(β -D-glucopyranosyloxy)-4-[(4-methylthiophenyl)-methyl]-1*H*-pyrazole

55 [0075] The title compound was prepared in a similar manner to that described in Example 35 using 5-ethyl-4-[(4-meth-

5 $\text{ylthiophenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl-\beta-D-glucopyranosyloxy)-1H-pyrazole$ instead of $4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl-\beta-D-glucopyranosyloxy)-1H-pyrazole$.

10 $^1\text{H-NMR}$ (500MHz, CD_3OD) δ ppm:

15 1.06 (3H, t, $J=7.6\text{Hz}$), 2.42 (3H, s), 2.47 (2H, q, $J=7.6\text{Hz}$), 3.25-3.45 (4H, m), 3.60-3.80 (3H, m), 3.80-3.90 (1H, m), 5.00-5.10 (1H, m), 7.10-7.20 (4H, m)

Example 45

3-(β -D-Glucopyranosyloxy)-4-[(4-isopropylphenyl)methyl]-5-methyl-1H-pyrazole

20 [0076] The title compound was prepared in a similar manner to that described in Example 35 using $4-[(4-isopropylphenyl)-methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl-\beta-D-glucopyranosyloxy)-1H-pyrazole$ instead of $4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl-\beta-D-glucopyranosyloxy)-1H-pyrazole$.

25 $^1\text{H-NMR}$ (500MHz, CD_3OD) δ ppm:

30 1.20 (6H, d, $J=6.9\text{Hz}$), 2.05 (3H, s), 2.75-2.90 (1H, m), 3.25-3.45 (4H, m), 3.55-3.90 (4H, m), 5.00-5.10 (1H, m), 7.00-7.15 (4H, m)

Example 46

3-(β -D-Glucopyranosyloxy)-4-[(4-methylthiophenyl)methyl]-5-trifluoromethyl-1H-pyrazole

35 [0077] The title compound was prepared in a similar manner to that described in Example 35 using $4-[(4-methylthiophenyl)-methyl]-3-(2,3,4,6-tetra-O-acetyl-\beta-D-gluco-pyranosyloxy)-5-trifluoromethyl-1H-pyrazole$ instead of $4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl-\beta-D-glucopyranosyloxy)-1H-pyrazole$.

40 $^1\text{H-NMR}$ (500MHz, CD_3OD) δ ppm:

45 2.42 (3H, s), 3.25-3.50 (4H, m), 3.69 (1H, dd, $J=4.9, 12.0\text{Hz}$), 3.75-3.90 (3H, m), 4.90-5.10 (1H, m), 7.10-7.20 (4H, m)

Example 47

4-Benzyl-3-(β -D-glucopyranosyloxy)-5-trifluoromethyl-1H-pyrazole

50 [0078] The title compound was prepared in a similar manner to that described in Example 35 using $4\text{-benzyl-3-(2,3,4,6-tetra-O-acetyl-\beta-D-glucopyranosyloxy)-5-trifluoromethyl-1H-pyrazole}$ instead of $4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl-\beta-D-glucopyranosyloxy)-1H-pyrazole$.

55 $^1\text{H-NMR}$ (500MHz, CD_3OD) δ ppm:

60 3.25-3.45 (4H, m), 3.67 (1H, dd, $J=5.3, 12.0\text{Hz}$), 3.80-3.95 (3H, m), 4.97 (1H, d, $J=7.4\text{Hz}$), 7.05-7.25 (5H, m)

Example 48

3-(β -D-Glucopyranosyloxy)-4-[(4-methoxyphenyl)methyl]-5-trifluoromethyl-1H-pyrazole

65 [0079] The title compound was prepared in a similar manner to that described in Example 35 using $4-[(4-methoxyphenyl)-methyl]-3-(2,3,4,6-tetra-O-acetyl-\beta-D-gluco-pyranosyloxy)-5-trifluoromethyl-1H-pyrazole$ instead of $4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl-\beta-D-glucopyranosyloxy)-1H-pyrazole$.

70 $^1\text{H-NMR}$ (500MHz, CD_3OD) δ ppm:

75 3.25-3.45 (4H, m), 3.67 (1H, d, $J=5.4, 12.1\text{Hz}$), 3.73 (3H, s), 3.75-3.90 (3H, m), 4.90-5.00 (1H, m), 6.70-6.85 (2H, m), 7.05-7.15 (2H, m)

Example 49

3-(β -D-Glucopyranosyloxy)-4-[(4-methoxyphenyl)methyl]-5-methyl-1H-pyrazole

80 [0080] The title compound was prepared in a similar manner to that described in Example 35 using $4-[(4-methoxyphenyl)-methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl-\beta-D-glucopyranosyloxy)-1H-pyrazole$ instead of $4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl-\beta-D-glucopyranosyloxy)-1H-pyrazole$.

85 $^1\text{H-NMR}$ (500MHz, CD_3OD) δ ppm:

90 2.04 (3H, s), 3.25-3.45 (4H, m), 3.55-3.75 (3H, m), 3.73 (3H, s), 3.80-3.90 (1H, m), 5.00-5.10 (1H, m), 6.75-6.85 (2H, m), 7.05-7.15 (2H, m)

Example 504-Benzyl-3-(β -D-glucopyranosyloxy)-5-methyl-1*H*-pyrazole

5 [0081] The title compound was prepared in a similar manner to that described in Example 35 using 4-benzyl-5-methyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole instead of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.

1 H-NMR (500MHz, CD₃OD) δ ppm:

2.05 (3H, s), 3.25-3.45 (4H, m), 3.60-3.90 (4H, m), 5.00-5.10 (1H, m), 7.05-7.25 (5H, m)

10

Example 513-(β -D-Glucopyranosyloxy)-4-[(4-methoxyphenyl)methyl]-1,5-dimethylpyrazole

15 [0082] The title compound was prepared in a similar manner to that described in Example 35 using 4-[(4-methoxyphenyl)-methyl]-1,5-dimethyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)pyrazole instead of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.

1 H-NMR (500MHz, CD₃OD) δ ppm:

2.06 (3H, s), 3.25-3.45 (4H, m), 3.55-3.70 (6H, m), 3.73 (3H, s), 3.75-3.90 (1H, m), 5.00-5.10 (1H, m), 6.70-6.80 (2H, m), 7.05-7.15 (2H, m)

20

Example 523-(β -D-Glucopyranosyloxy)-1-methyl-4-[(4-methylthiophenyl)methyl]-5-trifluoromethylpyrazole

25 [0083] The title compound was prepared in a similar manner to that described in Example 35 using 1-methyl-4-[(4-methylthiophenyl)methyl]-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethylpyrazole instead of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.

1 H-NMR (500MHz, CD₃OD) δ ppm:

30 2.42 (3H, s), 3.30-3.50 (4H, m), 3.69 (1H, dd, J=4.7, 12.0Hz), 3.75-3.90 (6H, m), 5.25-5.35 (1H, m), 7.05-7.20 (4H, m)

Example 531-Ethyl-3-(β -D-glucopyranosyloxy)-4-[(4-methylthiophenyl)-methyl]-5-trifluoromethylpyrazole

35 [0084] The title compound was prepared in a similar manner to that described in Example 35 using 1-ethyl-4-[(4-methylthiophenyl)methyl]-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethylpyrazole instead of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.

1 H-NMR (500MHz, CD₃OD) δ ppm:

40 1.38 (3H, t, J=7.1Hz), 2.42 (3H, s), 3.30-3.50 (4H, m), 3.60-3.75 (1H, m), 3.75-3.90 (1H, m), 4.14 (2H, q, J=7.1Hz), 5.25-5.35 (1H, m), 7.05-7.20 (4H, m)

Example 543-(β -D-Glucopyranosyloxy)-4-[(4-methylthiophenyl)methyl]-1-propyl-5-trifluoromethylpyrazole

45 [0085] The title compound was prepared in a similar manner to that described in Example 35 using 4-[(4-methylthiophenyl)-methyl]-1-propyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethylpyrazole instead of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.

1 H-NMR (500MHz, CD₃OD) δ ppm:

50 0.90 (3H, t, J=7.4Hz), 1.75-1.90 (2H, m), 2.42 (3H, s), 3.30-3.50 (4H, m), 3.69 (1H, dd, J=4.9, 12.0Hz), 3.75-3.90 (3H, m), 4.00-4.10 (2H, m), 5.25-5.35 (1H, m), 7.05-7.20 (4H, m)

Example 55

55

3-(β -D-Glucopyranosyloxy)-5-methyl-4-[(4-methylphenyl)-methyl]-1*H*-pyrazole

[0086] 5-Methyl-4-[(4-methylphenyl)methyl]-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole was

prepared in a similar manner to that described in Example 15 using 1,2-dihydro-5-methyl-4-[(4-methylphenyl)methyl]-3*H*-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3*H*-pyrazol-3-one. Then, the title compound was prepared in a similar manner to that described in Example 35 using 5-methyl-4-[(4-methylphenyl)methyl]-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole instead of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.

5 1 H-NMR (500MHz, CD₃OD) δ ppm:

2.04 (3H, s), 2.26 (3H, s), 3.25-3.45 (4H, m), 3.55-3.90 (4H, m), 5.00-5.10 (1H, m), 6.95-7.15 (4H, m)

10 Example 56

4-[(4-Ethylphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-methyl-1*H*-pyrazole

[0087] 4-[(4-Ethylphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole was prepared in a similar manner to that described in Example 15 using 4-[(4-ethylphenyl)methyl]-1,2-dihydro-5-methyl-3*H*-pyrazol-3-one instead of 1,2-dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3*H*-pyrazol-3-one. Then, the title compound was prepared in a similar manner to that described in Example 35 using 4-[(4-ethylphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole instead of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.

15 1 H-NMR (500MHz, CD₃OD) δ ppm:

20 1.18 (3H, t, J=7.6Hz), 2.04 (3H, s), 2.57 (2H, q, J=7.6Hz), 3.25-3.45 (4H, m), 3.55-3.90 (4H, m), 5.00-5.10 (1H, m), 6.95-7.20 (4H, m)

25 Example 57

3-(β -D-Glucopyranosyloxy)-4-[(4-methylphenyl)methyl]-5-trifluoromethyl-1*H*-pyrazole

[0088] 4-[(4-Methylphenyl)methyl]-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethyl-1*H*-pyrazole was prepared in a similar manner to that described in Example 26 using 1,2-dihydro-4-[(4-methylphenyl)methyl]-5-trifluoromethyl-3*H*-pyrazol-3-one instead of 1,2-dihydro-4-[(4-methylthiophenyl)methyl]-5-trifluoromethyl-3*H*-pyrazol-3-one. Then, the title compound was prepared in a similar manner to that described in Example 35 using 4-[(4-methylphenyl)-methyl]-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethyl-1*H*-pyrazole instead of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.

30 1 H-NMR (500MHz, CD₃OD) δ ppm:

2.25 (3H, s), 3.20-3.45 (4H, m), 3.55-3.70 (1H, m), 3.70-3.90 (3H, m), 4.80-4.95 (1H, m), 6.90-7.15 (4H, m)

35

Example 58

4-[(4-Ethylphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-trifluoromethyl-1*H*-pyrazole

[0089] 4-[(4-Ethylphenyl)methyl]-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethyl-1*H*-pyrazole was prepared in a similar manner to that described in Example 26 using 4-[(4-ethylphenyl)methyl]-1,2-dihydro-5-trifluoromethyl-3*H*-pyrazol-3-one instead of 1,2-dihydro-4-[(4-methylthiophenyl)methyl]-5-trifluoromethyl-3*H*-pyrazol-3-one. Then, the title compound was prepared in a similar manner to that described in Example 35 using 4-[(4-ethylphenyl)-methyl]-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethyl-1*H*-pyrazole instead of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.

40 1 H-NMR (500MHz, CD₃OD) δ ppm:

1.18 (3H, t, J=7.6Hz), 2.50-2.60 (2H, m), 3.15-3.40 (4H, m), 3.55-3.65 (1H, m), 3.70-3.90 (3H, m), 4.80-4.95 (1H, m), 6.95-7.15 (4H, m)

50 Example 59

3-(β -D-Glucopyranosyloxy)-4-[(4-isopropylphenyl)methyl]-5-trifluoromethyl-1*H*-pyrazole

[0090] 4-[(4-Isopropylphenyl)methyl]-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethyl-1*H*-pyrazole was prepared in a similar manner to that described in Example 26 using 1,2-dihydro-4-[(4-isopropylphenyl)-methyl]-5-trifluoromethyl-3*H*-pyrazol-3-one instead of 1,2-dihydro-4-[(4-methylthiophenyl)methyl]-5-trifluoro-methyl-3*H*-pyrazol-3-one. Then, the title compound was prepared in a similar manner to that described in Example 35 using 4-[(4-isopropylphenyl)methyl]-3-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethyl-1*H*-pyrazole instead

of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.

¹H-NMR (500MHz, CD₃OD) δ ppm:

1.20 (6H, d, J=6.9Hz), 2.75-2.85 (1H, m), 3.15-3.40 (4H, m), 3.55-3.65 (1H, m), 3.70-3.90 (3H, m), 4.80-4.95 (1H, m), 7.00-7.15 (4H, m)

5

Example 60

4-[(4-Chlorophenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-trifluoromethyl-1*H*-pyrazole

10 [0091] 4-[(4-Chlorophenyl)methyl]-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethyl-1*H*-pyrazole was prepared in a similar manner to that described in Example 26 using 4-[(4-chlorophenyl)methyl]-1,2-dihydro-5-trifluoromethyl-3*H*-pyrazol-3-one instead of 1,2-dihydro-4-[(4-methylthiophenyl)methyl]-5-trifluoromethyl-3*H*-pyrazol-3-one. Then, the title compound was prepared in a similar manner to that described in Example 35 using 4-[(4-chlorophenyl)-methyl]-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-5-trifluoromethyl-1*H*-pyrazole instead of 4-[(4-isopropoxyphenyl)methyl]-5-methyl-3-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-1*H*-pyrazole.

15 ¹H-NMR (500MHz, CD₃OD) δ ppm:

3.20-3.40 (4H, m), 3.55-3.70 (1H, m), 3.75-3.90 (3H, m), 4.80-4.95 (1H, m), 7.10-7.25 (4H, m)

20

Example 61

3-(β -D-Glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-5-methyl-1-propylpyrazole

25 [0092] To a suspension of 3-(β -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-5-methyl-1*H*-pyrazole (50mg) and cesium carbonate (0.20g) in *N,N*-dimethylformamide (1mL) was added iodopropane (0.036mL) at 50°C, and the mixture was stirred overnight. Water was added to the reaction mixture, and the resulting mixture was purified by solid phase extraction on ODS (washing solvent: distilled water, eluent: methanol). The resulting semi-purified material was purified by column chromatography on silica gel (eluent: dichloromethane/methanol = 8/1) to give 3-(β -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-5-methyl-1-propylpyrazole (28mg).

30 ¹H-NMR (500MHz, CD₃OD) δ ppm:

0.87 (3H, t, J=7.4Hz), 1.26 (6H, d, J=6.0Hz), 1.65-1.80 (2H, m), 2.07 (3H, s), 3.25-3.45 (4H, m), 3.55-3.75 (3H, m), 3.75-3.95 (3H, m), 4.40-4.60 (1H, m), 5.00-5.10 (1H, m), 6.70-6.80 (2H, m), 7.00-7.10 (2H, m)

Example 62

1-Ethyl-3-(β -D-glucopyranosyloxy)-4-[(4-isopropylphenyl)-methyl]-5-methylpyrazole

35 [0093] The title compound was prepared in a similar manner to that described in Example 61 using iodoethane instead of iodopropane.

40 ¹H-NMR (500MHz, CD₃OD) δ ppm: 1.26 (6H, d, J=6.0Hz), 1.29 (3H, t, J=7.2Hz), 2.08 (3H, s), 3.25-3.45 (4H, m), 3.55-3.75 (3H, m), 3.75-3.90 (1H, m), 3.96 (2H, q, J=7.2Hz), 4.40-4.60 (1H, m), 5.00-5.10 (1H, m), 6.70-6.80 (2H, m), 7.00-7.10 (2H, m)

50

Example 63

1-Ethyl-3-(β -D-glucopyranosyloxy)-4-[(4-methoxyphenyl)-methyl]-5-methylpyrazole

55 [0094] The title compound was prepared in a similar manner to that described in Example 61 using 3-(β -D-glucopyranosyloxy)-4-[(4-methoxyphenyl)methyl]-5-methyl-1*H*-pyrazole instead of 3-(β -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-5-methyl-1*H*-pyrazole and using iodoethane instead of iodopropane.

50 ¹H-NMR (500MHz, CD₃OD) δ ppm:

1.29 (3H, t, J=7.1Hz), 2.07 (3H, s), 3.20-3.45 (4H, m), 3.55-3.75 (6H, m), 3.82 (1H, dd, J=2.0, 12.0Hz), 3.90-4.05 (2H, m), 5.00-5.10 (1H, m), 6.70-6.85 (2H, m), 7.05-7.15 (2H, m)

55

Example 64

3-(β -D-Glucopyranosyloxy)-4-[(4-methoxyphenyl)methyl]-5-methyl-1-propylpyrazole

60 [0095] The title compound was prepared in a similar manner to that described in Example 61 using 3-(β -D-glucopy-

5-methyl-1*H*-pyrazole instead of 3-(β -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-5-methyl-1*H*-pyrazole.

1 H-NMR (500MHz, CD₃OD) δ ppm:

5 0.87 (3H, t, J=7.5Hz), 1.65-1.80 (2H, m), 2.07 (3H, s), 3.35-3.45 (4H, m), 3.60-3.75 (3H, m), 3.73 (3H, s), 3.75-3.85 (1H, m), 3.85-3.95 (2H, m), 5.00-5.10 (1H, m), 6.70-6.85 (2H, m), 7.00-7.15 (2H, m)

Example 65

1-Ethyl-4-[(4-ethoxyphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-methylpyrazole

10 [0096] The title compound was prepared in a similar manner to that described in Example 61 using 4-[(4-ethoxyphenyl)-methyl]-5-methyl-3-(β -D-glucopyranosyloxy)-1*H*-pyrazole instead of 3-(β -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-5-methyl-1*H*-pyrazole and using iodoethane instead of iodopropane.

1 H-NMR (500MHz, CD₃OD) δ ppm:

15 1.28 (3H, t, J=7.4Hz), 1.34 (3H, t, J=7.2Hz), 2.07 (3H, s), 3.25-3.45 (4H, m), 3.55-3.75 (3H, m), 3.75-3.85 (1H, m), 3.90-4.00 (4H, m), 5.00-5.10 (1H, m), 6.70-6.85 (2H, m), 7.00-7.15 (2H, m)

Example 66

4-[(4-Ethoxyphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-methyl-1-propylpyrazole

20 [0097] The title compound was prepared in a similar manner to that described in Example 61 using 4-[(4-ethoxyphenyl)-methyl]-5-methyl-3-(β -D-glucopyranosyloxy)-1*H*-pyrazole instead of 3-(β -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-5-methyl-1*H*-pyrazole.

25 1 H-NMR (500MHz, CD₃OD) δ ppm:

0.87 (3H, t, J=7.6Hz), 1.34 (3H, t, J=7.1Hz), 1.65-1.80 (2H, m), 2.07 (3H, s), 3.25-3.45 (4H, m), 3.55-3.75 (3H, m), 3.81 (1H, dd, J=2.1, 12.1Hz), 3.85-4.05 (4H, m), 5.00-5.10 (1H, m), 6.70-6.85 (2H, m), 7.00-7.15 (2H, m)

Example 67

1-Ethyl-4-[(4-ethylphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-methylpyrazole

30 [0098] The title compound was prepared in a similar manner to that described in Example 61 using 4-[(4-ethylphenyl)-methyl]-5-methyl-3-(β -D-glucopyranosyloxy)-1*H*-pyrazole instead of 3-(β -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-5-methyl-1*H*-pyrazole and using iodoethane instead of iodopropane.

35 1 H-NMR (500MHz, CD₃OD) δ ppm:

1.17 (3H, t, J=7.6Hz), 1.28 (3H, t, J=7.2Hz), 2.06 (3H, s), 2.56 (2H, q, J=7.6Hz), 3.25-3.45 (4H, m), 3.55-3.75 (3H, m), 3.75-3.85 (1H, m), 3.90-4.00 (2H, m), 5.00-5.10 (1H, m), 7.00-7.15 (4H, m)

40 Example 68

4-[(4-Ethylphenyl)methyl]-3-(β -D-glucopyranosyloxy)-5-methyl-1-propylpyrazole

45 [0099] The title compound was prepared in a similar manner to that described in Example 61 using 4-[(4-ethylphenyl)-methyl]-5-methyl-3-(β -D-glucopyranosyloxy)-1*H*-pyrazole instead of 3-(β -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-5-methyl-1*H*-pyrazole.

50 1 H-NMR (500MHz, CD₃OD) δ ppm:

0.87 (3H, t, J=7.4Hz), 1.17 (3H, t, J=7.6Hz), 1.65-1.80 (2H, m), 2.06 (3H, s), 2.56 (2H, q, J=7.6Hz), 3.25-3.45 (4H, m), 3.60-3.95 (6H, m), 5.00-5.10 (1H, m), 7.00-7.15 (4H, m)

55 Example 69

1-Butyl-3-(β -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)-methyl]-5-methylpyrazole

55 [0100] The title compound was prepared in a similar manner to that described in Example 61 using bromobutane instead of iodopropane.

1 H-NMR (500MHz, CD₃OD) δ ppm:

0.92 (3H, t, J=7.4Hz), 1.20-1.40 (8H, m), 1.60-1.75 (2H, m), 2.07 (3H, s), 3.25-3.45 (4H, m), 3.55-3.75 (3H, m), 3.81

(1H, dd, J=2.1, 12.0Hz), 3.91 (2H, t, J=7.2Hz), 4.45-4.55 (1H, m), 5.00-5.10 (1H, m), 6.70-6.80 (2H, m), 7.00-7.10 (2H, m)

Example 70

3-(β -D-Glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-1-isopropyl-5-methylpyrazole

[0101] The title compound was prepared in a similar manner to that described in Example 61 using 2-bromopropane instead of iodopropane.

¹⁰ ¹H-NMR (500MHz, CD₃OD) δ ppm:

1.26 (6H, d, J=6.0Hz), 1.30-1.40 (6H, m), 2.08 (3H, s), 3.15-3.45 (4H, m), 3.55-3.75 (3H, m), 3.78 (1H, dd, J=2.3, 12.0Hz), 4.35-4.45 (1H, m), 4.45-4.55 (1H, m), 5.00-5.10 (1H, m), 6.70-6.80 (2H, m), 7.00-7.10 (2H, m)

Test Example 1

¹⁵ Assay for inhibitory effect on human SGLT2 activity

1) Construction of the plasmid vector expressing human SGLT2

[0102] Preparation of the cDNA library for PCR amplification was performed by reverse transcription of a total RNA derived from human kidney (Ori gene) with oligo dT as the primer, using Super Script preamplification system (Gibco-BRL: LIFE TECHNOLOGIES). The DNA fragment coding for human SGLT2 was amplified by the PCR reaction, in which the human kidney cDNA library described above was used as the template and the following oligo nucleotides 0702F and 0712R, presented as sequence number 1 and 2 respectively, were used as the primers. The amplified DNA fragment was ligated into pCR (Invitrogen), a vector for cloning, according to standard method of the kit. The *Escherichia coli* HB101 was transformed according to usual method and then selection of the transformants was performed on the LB agar medium containing 50 μ g/mL of kanamycin. After plasmid DNA was extracted and purified from the one of the transformants, amplifying of the DNA fragment coding for human SGLT2 was performed by the PCR reaction, in which the following oligo nucleotides 0714F and 0715R, presented as sequence number 3 and 4 respectively, were used as the primers. The amplified DNA fragment was digested with restriction enzymes, Xho I and Hind III, and then purified with Wizard purification System (Promega). This purified DNA fragment was inserted at into the corresponding restriction sites of pcDNA3.1 (-) Myc/His-B (Invitrogen), a vector for expressing of fusion protein. The *Escherichia coli* HB101 was transformed according to the usual method and then selection of the transformant was performed on the LB agar medium containing 50 μ g/mL of ampicillin. After plasmid DNA was extracted and purified from this transformant, the base sequence of the DNA fragment inserted at the multi-cloning sites of the vector pcDNA3.1 (-) Myc/His - B was analyzed. This clone had a single base substitution (ATC which codes for the isoleucine-433 was substituted by GTC) compared with the human SGLT2 reported by Wells *et al* (Am. J. Physiol., Vol. 263, pp. 459-465 (1992)). Sequentially, a clone in which valine is substituted for isoleucine-433 was obtained. This plasmid vector expressing human SGLT2 in which the peptide presented as sequence number 5 is fused to the carboxyl terminal alanine residue was designated ⁴⁰ KL29.

Sequence Number 1 ATGGAGGAGCACACAGAGGC

Sequence Number 2 GGCATAGAAGCCCCAGAGGA

Sequence Number 3 AACCTCGAGATGGAGGAGCACACAGAGGC

Sequence Number 4 AACAAAGCTTGGCATAGAAGCCCCAGAGGA

Sequence Number 5 KLGPEQKLISEEDLNSAVDHHHHHH

2) Preparation of the cells expressing transiently human SGLT2

[0103] KL29, the plasmid expressing human SGLT2, was transfected into COS-7 cells (RIKEN CELL BANK RCB0539) by electroporation. Electroporation was performed with GENE PULSER II (Bio-Rad Laboratories) under the condition: 0.290 KV, 975 μ F, 2 \times 10⁶ cells of COS-7 cell and 20 μ g of KL29 in 500 μ L of OPTI-MEM I medium (Gibco-BRL: LIFE TECHNOLOGIES) in the 0.4 cm type cuvette. After the gene transfer, the cells were harvested by centrifugation and resuspended with OPTI-MEM I medium (1mL/cuvette). To each well in 96-wells plate, 125 μ L of this cell suspension was added. After overnight culture at 37 °C under 5 % CO₂, 125 μ L of DMEM medium which is containing 10 % of fetal bovine serum (Sanko Jyunyaku), 100 units/mL sodium penicillin G (Gibco-BRL: LIFE TECHNOLOGIES), 100 μ g/mL streptomycin sulfate (Gibco-BRL: LIFE TECHNOLOGIES) was added to each well. These cells were cultured until the next day and then they were used for the measurement of the inhibitory activity against the uptake of methyl- α -D-glucopyranoside.

3) Measurement of the inhibitory activity against the uptake of methyl- α -D-glucopyranoside

[0104] After a test compounds was dissolved in dimethyl sulfoxide and diluted with the uptake buffer (a pH 7.4 buffer containing 140 mM sodium chloride, 2 mM potassium chloride, 1 mM calcium chloride, 1 mM magnesium chloride, 5 mM methyl- α -D-glucopyranoside, 10 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethane sulfonic acid and 5 mM tris(hydroxymethyl)aminomethane), each diluent was used as test sample for measurement of the inhibitory activity. After removal of the medium of the COS-7 cells expressing transiently human SGLT2, to each well 200 μ L of the pretreatment buffer (a pH 7.4 buffer containing 140 mM choline chloride, 2 mM potassium chloride, 1 mM calcium chloride, 1 mM magnesium chloride, 10 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethane sulfonic acid and 5 mM tris(hydroxymethyl)aminomethane) was added, and the cells were incubated at 37 °C for 10 minutes. After the pretreatment buffer was removed, 200 μ L of the same buffer was added again, and the cells were incubated at 37 °C for 10 minutes. The buffer for measurement was prepared by adding of 7 μ L of methyl- α -D-(U-14C)glucopyranoside(Amersham Pharmacia Biotech) to 525 μ L of the prepared test sample. For the control, the buffer for measurement without test compound was prepared. For estimate of the basal uptake in the absence of test compound and sodium, the buffer for measurement of the basal uptake, which contains 140 mM choline chloride in place of sodium chloride, was prepared similarly. After the pretreatment buffer was removed, 75 μ L of the each buffer for measurement was added to each well, the cells were incubated at 37 °C for 2 hours. After the buffer for measurement was removed, 200 μ L of the washing buffer (a pH 7.4 buffer containing 140 mM choline chloride, 2 mM potassium chloride, 1 mM calcium chloride, 1 mM magnesium chloride, 10 mM methyl- α -D-glucopyranoside, 10 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethane sulfonic acid and 5 mM tris(hydroxymethyl)aminomethane) was added to each well and immediately removed. After two additional washings, the cells were solubilized by addition of 75 μ L of 0.2 N sodium hydroxide to each well. After the cell lysates were transferred to the PicoPlate (Packard) and 150 μ L of MicroScint-40 (Packard) was added to each well, the radioactivity was measured with microplate scintillation counter TopCount (Packard). The difference in uptake was obtained as 100 % value by subtracting the radioactivity in the basal uptake from that in control and then the concentrations at which 50 % of uptake were inhibited (IC₅₀) were calculated from the concentration-inhibition curve by least square method. The results are shown in the following Table 1.

[Table 1]

Test compound	IC ₅₀ value (nM)
Example 35	181
Example 36	441
Example 37	346
Example 38	702
Example 39	185
Example 43	84
Example 44	509
Example 45	441
Example 46	679
Example 48	415

[Table 1] (continued)

Test compound	IC ₅₀ value (nM)
Example 49	383
Example 52	835
Example 55	280
Example 56	190
Example 58	634
WAY-123783	>100000

Test Example 2

Assay for the facilitatory effect on urinary glucose excretion

Method A)

[0105] As experimental animal, overnight fasted SD rats (SLC, male, 5 weeks of age, 120-150g) were used. Test compound (25.40 mg) was suspended in 762 μ L of ethanol and dissolved by adding of 3.048 mL of polyethylene glycol 400 and 3.81 mL of saline and then 3.3 mg/mL solution was prepared. A part of this solution was diluted with the solvent (saline: polyethylene glycol 400: ethanol = 5: 4: 1) and then each solution at the concentration of 3.3, 1 or 0.33 (mg/mL) was prepared. Each of these solutions was subcutaneously administered to the rats at the dose of 3 mL/kg (10, 3 and 1 mg/kg). For the control, just the solvent (saline: polyethylene glycol 400: ethanol = 5: 4: 1) was subcutaneously administered at the dose of 3 mL/kg. Immediately after this subcutaneous administration, 200 g/L glucose solution was orally administered at the dose of 10 mL/kg (2 g/kg). The subcutaneous administration was performed with 26G needle and 1 mL syringe. The oral administration was performed with gastric tube for rat and 2.5 mL syringe. The head count in one group was 3. Collection of urine was performed in metabolic cage after these administrations were finished. The sampling time for collection of urine was 4 hours after the glucose administration. After collection of urine was finished, the urine volume was recorded and the urinary glucose concentration was measured. The glucose concentration was measured with a kit for laboratory test: Glucose B-Test WAKO (Wako Pure Chemical Industries, Ltd.). The amount of urinary glucose excretion in 4 hours per 1 body was calculated from urine volume and urinary glucose concentration.

Method B)

[0106] As experimental animal, overnight fasted SD rats (SLC, male, 7 weeks of age, 180-220g) were used. A test compound (10 mg) was suspended or dissolved in 300 μ L of ethanol and dissolved by adding of 1.2 mL of polyethylene glycol 400 and 1.5 mL of saline and then 3.3 mg/mL solution was prepared. A part of this solution was diluted with the solvent (saline: polyethylene glycol 400: ethanol = 5: 4: 1) and then each solution at the concentration of 3.3, 0.33 or 0.033 (mg/mL) was prepared. After the body weights of the rats were measured, the test compound solution was administered by intravenous injection to the tail vein at the dose of 3 mL/kg (10, 1 and 0.1 mg/kg). For the control, just the solvent (saline: polyethylene glycol 400: ethanol = 5: 4: 1) was administered by intravenous injection to the tail vein at the dose of 3 mL/kg. Immediately after this intravenous administration, 200 g/L glucose solution was orally administered at the dose of 10 mL/kg (2 g/kg). The intravenous administration was performed with 26G needle and 1 mL syringe. The oral administration was performed with gastric tube for rat and 2.5 mL syringe. The head count in one group was 3. Collection of urine was performed in metabolic cage after the glucose administration was finished. The sampling time for collection of urine was 24 hours after the glucose administration. After collection of urine was finished, the urine volume was recorded and the urinary glucose concentration was measured. The glucose concentration was measured with a kit for laboratory test: Glucose B-Test WAKO (Wako Pure Chemical Industries, Ltd.). The amount of urinary glucose excretion in 24 hours per 200 g of body weight was calculated from urine volume, urinary glucose concentration and body weight.

The results are shown in the following Table 2.

[Table 2]

Test compound	Method	Dose (mg/kg)	Amount of Urinary Glucose Excretion (mg)
Example 35	B	0.1	16
		1	74
		10	188
Example 45	A	1	22.1
		3	83.2
		10	153.3
	B	0.1	2
		1	45
		10	132

Test Example 320 Acute toxicity test

Method A)

25 [0107] By adding 0.5% sodium carboxymethylcellulose solution to the test compound, 100 mg/mL suspension was prepared. As experimental animal, male 6-7 weeks of age ICR mice fasted for 4 hours (Clea Japan, 28-33g, 5 animals in each group) were used. The test suspension described above was orally administered to the experimental animals described above at the dose of 10 mL/kg (1000 mg/kg) and then observation was performed until 24 hours after the administration.

30 Method B)

35 [0108] By adding of the solvent (saline: polyethylene glycol 400: ethanol = 5 : 4: 1) to the test compound, 200 mg/mL suspension was prepared. As experimental animal, male 5 weeks of age ICR mice fasted for 4 hours (Clea Japan, 26-33g, 5 animals in each group) were used. The test suspension described above was subcutaneously administered to the experimental animals described above at the dose of 3 mL/kg (600 mg/kg) and then observation was performed until 24 hours after the administration.

40 [0109] The results are shown in the following Table 3.

[Table 3]

Test compound	Method	Death number
Example 35	B	0 / 5
Example 45	A	0 / 5

45 Industrial Applicability

50 [0110] The glucopyranosyloxybenzylbenzene derivatives represented by the above general formula (I) of the present invention and pharmaceutically acceptable salts thereof have an inhibitory activity on human SGLT2 and exert an excellent hypoglycemic effect by excreting excess glucose in the urine through preventing the reabsorption of glucose at the kidney. Therefore, agents for the prevention or treatment of diabetes, diabetic complications, obesity or the like can be provided comprising the glucopyranosyloxybenzylbenzene derivative represented by the above general formula (I) of the present invention or pharmaceutically acceptable salt thereof.


55 [0111] In addition, the compounds represented by the above general formulae (V) and (VII), and salts thereof are important as intermediates in the production of the compounds represented by the above general formula (I) and pharmaceutically acceptable salts thereof. Accordingly, the compounds represented by the above general formula (I) of the present invention and pharmaceutically acceptable salts thereof can be readily prepared via these compounds.

Claims

1. A glucopyranosyloxyypyrazole derivative represented by the general formula:

5


10



wherein R¹ represents a hydrogen atom or a lower alkyl group; one of Q¹ and T¹ represents a group represented by the formula:

15

20




while the other represents a lower alkyl group or a halo(lower alkyl) group; R² represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or a pharmaceutically acceptable salt thereof.

25

2. A glucopyranosyloxyypyrazole derivative as claimed in claim 1, represented by the general formula:

30


35



wherein R¹¹ represents a hydrogen atom or a straight-chained or branched alkyl group having 1 to 3 carbon atoms; one of Q¹¹ and T¹¹ represents a group represented by the formula:

40

45




while the other represents a straight-chained or branched alkyl group having 1 to 3 carbon atoms; and R²¹ represents a straight-chained or branched alkyl group having 1 to 4 carbon atoms, a straight-chained or branched alkoxy group having 1 to 3 carbon atoms or a straight-chained or branched alkylthio group having 1 to 3 carbon atoms, or a pharmaceutically acceptable salt thereof.


50

3. A glucopyranosyloxyypyrazole derivative as claimed in claim 1, represented by the general formula:

55



10 wherein R¹² represents a hydrogen atom, an ethyl group, a propyl group or an isopropyl group; one of Q¹² and T¹² represents a group represented by the formula:




20 while the other represents a methyl group; and R²² represents an ethyl group, an ethoxy group, an isopropoxy group or a methylthio group, or a pharmaceutically acceptable salt thereof.

25

4. A pharmaceutical composition comprising as an active ingredient a glucopyranosyloxyxypyrazole derivative as claimed in claim 1, 2 or 3, or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition as claimed in claim 4 wherein the composition is a human SGLT2 inhibitor.
6. A pharmaceutical composition as claimed in claim 4 wherein the composition is an agent for the prevention or treatment of diabetes.

30


7. A pharmaceutical composition as claimed in claim 4 wherein the composition is an agent for the prevention or treatment of obesity.
8. A glucopyranosyloxyxypyrazole derivative represented by the general formula:



45 wherein R¹ represents a hydrogen atom or a lower alkyl group; one of Q² and T² represents a 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy group, while the other represents a lower alkyl group or a halo(lower alkyl) group; and R² represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or a salt thereof.

50

9. A benzylpyrazole derivative represented by the general formula:



EP 1 213 296 A1

wherein R² represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and R³ represents a lower alkyl group, or a salt thereof.

5

10

15

20

25

30

35

40

45

50

55

INTERNATIONAL SEARCH REPORT		International application No. PCT/JP00/05678
A. CLASSIFICATION OF SUBJECT MATTER Int.Cl' C07H17/02, C07D231/20, A61K31/7056, A61P3/04, 3/10		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl' C07H17/02, C07D231/20, A61K31/7056, A61P3/04, 3/10		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS (STN), MEDLINE (STN), EMBASE (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, 524111, A (Department of Medicinal Chemistry and Analytical Chemistry), 28 December, 1993 (28.12.93) & US, 5264451, A	1-9
A	US, 5264451, A (American Home Products Corp.), 23 November, 1993 (23.11.93) & US, 5274111, A	1-9
A	KUEBAL B., 'Simple synthesis of 4-(heteroaryl methyl) phenols and their acylation.' Liebigs Ann. Chem., 1980, Vol.9, pages 1392 to 1401 & Database CAPLUS on STN, AMERICAN CHEMICAL SOCIETY (ACS), (Columbus, OH, USA), DN.94 : 47172	9
A	PEERCE B.E., 'Molecular mechanism of two noncompetitive inhibitors of sodium-glucose cotransporter : comparison of DCCD and PCMB.', Am. J. Physiol., 1993, Vol.264, No.2, Pt.1, pages G300 to G305 & Database CAPLUS on STN, AMERICAN CHEMICAL SOCIETY (ACS), (Columbus, OH, USA), DN.118 : 228571	5-7
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 06 November, 2000 (06.11.00)		Date of mailing of the international search report 14 November, 2000 (14.11.00)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

THIS PAGE BLANK (USPTO)

App. No. 10/735,179
Filed: December 12, 2003
Inventor: FRICK, et. al.
Docket No. DEAV2002/0086 US NP
PRIOR ART

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK